Cowen & Co initiates coverage on OSI Pharmaceuticals (Nasdaq: OSIP) with a Neutral.

Cowen analyst says, "Growing revenues associated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE